As filed with the Securities and Exchange Commission on December 11, 2014
Registration No. 333-200668
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Flexion Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 2834 | 26-1388364 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
10 Mall Road, Suite 301
Burlington, MA 01803
(781) 305-7777
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Michael D. Clayman, M.D.
Chief Executive Officer
Flexion Therapeutics, Inc.
10 Mall Road, Suite 301
Burlington, MA 01803
(781) 305-7777
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas A. Coll, Esq. Sean M. Clayton, Esq. Cooley LLP 500 Boylston Street, 14th Floor Boston, Massachusetts 02116 (617) 937-2300 |
Mitchell Bloom, Esq. Edward King, Esq. Ryan Sansom, Esq. Goodwin Procter LLP 53 State Street Boston, Massachusetts 02109 (617) 570-1000 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ¨
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. x 333-200668
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ¨ | Accelerated filer | ¨ | |||
Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | x |
This post-effective amendment shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.
Explanatory Note
This Post-Effective Amendment No. 1 (this Amendment) relates to the Registrants Registration Statement on Form S-1 (File No. 333-200668), as amended, declared effective on December 11, 2014 by the Securities and Exchange Commission. The Registrant is filing this Amendment for the sole purpose of replacing Exhibit 5.1 to the Registration Statement. This Amendment does not modify any provision of Part I or Part II of the Registration Statement other than Item 16(a) of Part II as set forth below.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 16. | Exhibits and financial statement schedules. |
(a) | Exhibits. |
See Exhibit Index immediately following the signature page.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Post-Effective Amendment No. 1 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, State of Massachusetts, on the 11th day of December, 2014.
FLEXION THERAPEUTICS, INC. | ||
By: | /s/ Michael D. Clayman, M.D. | |
Michael D. Clayman, M.D. President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ Michael D. Clayman, M.D. Michael D. Clayman, M.D. |
President, Chief Executive Officer and Member of the Board of Directors (Principal Executive Officer) |
December 11, 2014 | ||
/s/ Frederick W. Driscoll Frederick W. Driscoll |
Chief Financial Officer (Principal Financial and Accounting Officer) |
December 11, 2014 | ||
/s/ Patrick J. Mahaffy* Patrick J. Mahaffy |
Chairman of the Board of Directors | December 11, 2014 | ||
/s/ Samuel D. Colella* Samuel D. Colella |
Member of the Board of Directors | December 11, 2014 | ||
/s/ Heath Lukatch, Ph.D.* Heath Lukatch, Ph.D. |
Member of the Board of Directors | December 11, 2014 | ||
/s/ Sandesh Mahatme* Sandesh Mahatme |
Member of the Board of Directors | December 11, 2014 | ||
/s/ Ann Merrifield* Ann Merrifield |
Member of the Board of Directors | December 11, 2014 | ||
/s/ Alan Milinazzo* Alan Milinazzo |
Member of the Board of Directors | December 11, 2014 | ||
/s/ Andrew J. Schwab* Andrew J. Schwab |
Member of the Board of Directors | December 11, 2014 |
* Pursuant to power of attorney | ||
By: |
/s/ Michael D. Clayman, M.D. | |
Michael D. Clayman, M.D. |
EXHIBIT INDEX
Exhibit number |
Description | |
1.1 | Form of Underwriting Agreement. | |
3.1(1) | Form of Amended and Restated Certificate of Incorporation of the Registrant. | |
3.2(1) | Amended and Restated Bylaws of the Registrant. | |
4.1(2) | Form of Common Stock Certificate of the Registrant. | |
4.2(2) | Amended and Restated Investor Rights Agreement, dated December 3, 2012, by and among the Registrant and certain of its stockholders. | |
4.3(2) | Conversion, Amendment and Waiver Agreement, dated January 27, 2014, by and among the Registrant and certain of its stockholders. | |
5.1 | Opinion of Cooley LLP. | |
10.1+(2) | Form of Indemnity Agreement by and between the Registrant and its directors and officers. | |
10.2+(2) | Flexion Therapeutics, Inc. 2009 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder. | |
10.3+(2) | Flexion Therapeutics, Inc. 2013 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder. | |
10.4+(2) | Flexion Therapeutics, Inc. 2013 Employee Stock Purchase Plan. | |
10.5+(3) | Flexion Therapeutics, Inc. Non-Employee Director Compensation Policy, as revised. | |
10.6+(2) | Amended and Restated Offer Letter by and between the Registrant and Michael D. Clayman, M.D. | |
10.7+(3) | Amendment to Amended and Restated Offer Letter by and between the Registrant and Michael D. Clayman, M.D. | |
10.8+(2) | Amended and Restated Offer Letter by and between the Registrant and Neil Bodick, M.D., Ph.D. | |
10.9+(3) | Amendment to Amended and Restated Offer Letter by and between the Registrant and Neil Bodick, M.D., Ph.D. | |
10.10+(2) | Amended and Restated Offer Letter by and between the Registrant and Fred Driscoll. | |
10.11+(3) | Amendment to Amended and Restated Offer Letter by and between the Registrant and Fred Driscoll. | |
10.12*(2) | Out-License Agreement, dated June 12, 2009, by and between the Registrant (as successor in interest to Flexion Therapeutics AG) and AstraZeneca AB. | |
10.13*(2) | Out-License Agreement, dated September 3, 2010, by and between the Registrant and AstraZeneca AB. | |
10.14*(2) | Letter Agreement, dated December 3, 2012, by and between the Registrant and AstraZeneca AB. | |
10.15*(4) | Letter Agreement, dated March 17, 2014, by and between the Registrant and AstraZeneca AB. | |
10.16(2) | Credit and Security Agreement, dated January 3, 2013, by and between the Registrant and MidCap Financial SBIC, LP. | |
10.17(2) | Lease, dated February 22, 2013, by and between the Registrant and The Trustees of Mall Road Trust. | |
10.18+(5) | Flexion Therapeutics, Inc. Change in Control Bonus Plan. | |
23.1 | Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm. | |
23.2 | Consent of Cooley LLP. Reference is made to Exhibit 5.1. | |
24.1 | Power of Attorney. |
| Previously filed. |
+ | Indicates management contract or compensatory plan. |
* | Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission. |
(1) | Incorporated by reference to the Registrants Current Report on Form 8-K, filed with the SEC on February 19, 2014. |
(2) | Incorporated by reference to the Registrants Registration Statement on Form S-1 (File No. 333-193233), as amended. |
(3) | Incorporated by reference to the Registrants Annual Report on Form 10-K, filed with the SEC on March 28, 2014. |
(4) | Incorporated by reference to the Registrants Quarterly Report on Form 10-Q, filed with the SEC on May 12, 2014. |
(5) | Incorporated by reference to the Registrants Current Report on Form 8-K, filed with the SEC on September 2, 2014. |
Exhibit 5.1
![]() |
Sean M. Clayton
T: +1 858 550 6034
sclayton@cooley.com
December 11, 2014
Flexion Therapeutics, Inc.
10 Mall Road, Suite 301
Burlington, MA 01803
Ladies and Gentlemen:
We represent Flexion Therapeutics, Inc., a Delaware corporation (the Company), in connection with the filing, pursuant to Rule 462(d) of Regulation C promulgated under the Securities Act of 1933, of a Post-Effective Amendment No. 1 to a Registration Statement (No. 333-200668) on Form S-1 (the Registration Statement) with the Securities and Exchange Commission, including a related prospectus filed with the Registration Statement (the Prospectus), covering an underwritten public offering of up to 5,131,165 shares (the Shares) of the Companys common stock, par value $0.001, which includes up to 4,789,087 Shares to be sold by the Company (the Company Shares) and up to 342,078 Shares that may be sold by the Company pursuant to the exercise of an of an over-allotment option granted to the underwriters (the Overallotment Shares). The Registration Statement was declared effective on December 11, 2014.
In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related Prospectus, (b) the Companys Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as currently in effect and (c) the originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as copies. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought independently to verify such matters. Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion as to whether the laws of any particular jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Company Shares and the Overallotment Shares, when sold and issued against payment therefor as described in the Registration Statement and the related Prospectus, will be validly issued, fully paid and non-assessable.
4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM
Flexion Therapeutics, Inc.
December 11, 2014
Page Two
We consent to the reference to our firm under the caption Legal Matters in the Prospectus included in the Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement.
Sincerely,
Cooley LLP
By: |
/s/ Sean M. Clayton | |
Sean M. Clayton |
4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM
IZG ME+:Q>CO8]589%>8_$N(:=XGTO4+8!)W&6(Z MDHPP3_WUBNM?Q[H`M?.&HQ,N,A0K;OIM(S_*N,CDG^(7C6*XCB=-.LBN2PZJ M#G!_VFXX["FVB5H;/Q:_Y%FU_P"OI?\`T!J?XHG>#X4VVPX\VVMT;Z$+G^H_ M&F_%O_D6;7_K[7_T!JU+G23K?PYM[),"1[*%HR?[RJI'\L?C2ZCZ(XSPMK6O MZ3HL<>E:#]HMW)?S1"Y\PD]<@^P'X5?U'Q!XJU33Y[.X\-$Q3H4;]Q)Q[]?Q M_"F>"?&,&AV[:/KA>V:!R$=U)VYZJPZCG\.?I6SXB^(>FV-A(-.G6[NG4B/R MQ\JG^\3[=< )%_7FMTQY\?[V'/7<.WX@D?B*JV@KZZG+_Q2NG>$8[&SFS+JO`93_RQZL? MQ!`_X$:V_AKX6_X1KP;;PRQA;NY/GW&[J&(X4_08'X'UKRKP397'CCQ[9"YS M+I^D1@_-G:$1OD7\6/Y`^E?0$0`3`[5$/>DY';B/W-.-!;[O]$*Z!T*G!!X. M:YK4?AUH.H2F06IMG)R3`Q4?ET_2NGHK4X#F-.^'6@Z=,)?LK7,@.09W+`?\ M!Z?I72HNQ`H``'0#H*=10!CZIX4TK63NO[*.63IYBDH_Y@Y/XFJ^G>!M#TN4 M2V]@AD'(:5VD(^FXG'UKH**5@N%5KZPM]1@,%Y!'/">J2#(JS13`Y@?#?PZ) MO,^P'KG;YTFW\LUOV5C;Z?;B"UACAB7HD:[0*L44K(=RAJ6BV>L6Z0ZA;I<1 MQMO56)P#@C/'L35NV@2VMHX(E"1Q*$10>B@8`J2BF(R-6\+:5K;;]0LHY)`, M>8"5?'U3O`NA:9,);>P0R+R&E9I"#ZC<2*Z"BE9`(>E\6?%(\.^$Y( M89`MYJ&8(N>0N/G;\`0,^K"NVD(5